Advertisement
     Stock news arrow Stocks 

Main Menu
Stock news
Forex news
Forex Charts
Live Market News
Economic Calendar
Links
Forum
About
User Menu
My Favourites
Bookmark Us
 
 
Login Form





Lost Password?
No account yet? Register
StockTopsites.com
FXtopsites.com
TOP 100 INVESTING SITES
TOP 100 FINANCIAL SITES
TOP 100 FOREX SITES

FeedTheBull - Top Stock market and Finance Sites


ALL |0-9 |A |B |C |D |E |F |G |H |I |J |K |L |M |N |O |P |Q |R |S |T |U |V |W |X |Y |Z


ADVENTRX Pharmaceuticals Inc - ANX
 
  

 
 

Yahoo! Finance: ANX News

Latest Financial News for ADVENTRX PHARMACTL

Yahoo! Finance

Yahoo! Finance: ANX Financial Blogs

Latest Financial Financial Blogs for ADVENTRX PHARMACTL

Yahoo! Finance

MSN Money News - ANX

News about ADVENTRX Pharmaceuticals Inc

  • ADVENTRX Pharmaceuticals to Present at the Rodman

    (Tuesday, November 04, 2008 6:00 AM)

    SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that Mark Erwin, Senior Vice President, Operations of ADVENTRX, is scheduled to present at the

ANX - News and Analysis from Seeking Alpha

'ANX' Tag RSS Syndication from SeekingAlpha.com

  • Adventrx Plummets 80% On Cancer Drug Trial Results

    (Fri, 05 Oct 2007 04:45:35 -0400)

    H.S. Ayoub submits:

    Adventrx Pharmaceuticals (ANX) shares absolutely crashed on Monday by almost 80% as the company announced that a phase 2b clinical trial for its metastatic colorectal cancer treatment:

    ...did not demonstrate statistically significant improved safety in the trial's primary endpoint, a reduction in the proportion of patients reporting at least one hematological or gastrointestinal adverse event of grade 3 or greater.

    The company's shares closed at more than $2.50 last Friday before opening Monday's session at $0.81 and ended the day at $0.55. The company is now discussing the future course of this program, but is still optimistic about the other two programs ANX-530 and ANX-514.


    Complete Story...

  • Cancer Stocks Finish a Tough Quarter

    (Mon, 01 Oct 2007 06:46:36 -0400)

    ab analytical servicesAlan Brochstein, CFA submits:

    The universe of cancer stocks endured several challenges during the quarter, extending its losses subsequent to the ASCO meeting in early June. The median return of the group now is -9.9% on the year thus far and the average is +4.7% (demonstrating the skew that attracts people in the first place to the sector). The AMEX Biotech Index [BTK] is up about 9% on the year. The lists below, with data from StockVal, are comprised of domestic companies primarily. The total universe has...

  • Icahn Management Releases Latest 13F: Summary of Holdings

    (Thu, 16 Aug 2007 05:52:30 -0400)

    Lon Juricic submits: Carl Icahn's Icahn Management released its latest 13F for the quarter ended June 30, 2007. Below is a summary:

    New Positions:


    Complete Story »

  • Cancer Stocks: Tracking the Market

    (Mon, 09 Jul 2007 07:03:31 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: After plunging in the weeks following ASCO, cancer stocks moved with the market this week.

    The lists below, with data from StockVal, are comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week. If the reader believes that there are erroneous inclusions or exclusions, feel free to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it .

    There were even fewer outliers in this holiday-shortened week, with 4 double-digit gainers and just one double-digit decliner....

  • Cancer Stocks Hammered Once Again

    (Tue, 26 Jun 2007 03:47:21 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: After plunging in the week following ASCO and then underperforming the following week, cancer stocks were hammered yet again.

    The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.

    The 14 double-digit declines exceeded the 12 that plunged immediately following the ASCO meeting, with just a single double-digit gainer. The median return of -4.2% and the average...

  • Cancer Stocks Slide Again

    (Mon, 18 Jun 2007 08:18:26 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: After plunging in the week following ASCO, cancer-related stocks merely underperformed this week.

    The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.

    The number of double-digit declines decreased from 12 to just 4, but there were no double-digit gainers. The median return of 0.0 and the average return of -0.3 trailed the S&P 500 significantly (-1.6% and -2% respectively)....

  • Cancer Stocks Plunge Following ASCO Meeting

    (Mon, 11 Jun 2007 07:39:50 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: As they say, ?Buy the rumor, sell the news?. Or, was it ?Sell in May, and then go away??

    In any event, cancer-related stocks plunged in the week that followed the ASCO meeting in Chicago (June 1-5).

    Last week?s huge winner, Novacea (NOVC), gave back about 1/3 of its gains.


    Complete Story »

  • Cancer Stocks Soar With Annual ASCO Meeting

    (Mon, 04 Jun 2007 06:18:22 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: Cancer-related stocks soared during the holiday-shortened week as presentations began on June 1st at the ASCO annual meeting in Chicago.

    Last week?s big winner, Bioenvision (BIVN), received an offer from partner Genzyme (GENZ) at a disappointing premium but well ahead of multi-year lows reached in early May.

    The list below is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.


    Complete Story »

  • Cancer Stocks on the Go: Winners and Losers

    (Tue, 29 May 2007 05:35:19 -0400)

    ab analytical servicesAlan Brochstein, CFA submits: Later this week, the big event of the year for companies trying to treat cancer takes place in Chicago: the American Society of Clinical Oncology?s Annual Meeting. Not surprisingly, the universe of cancer stocks performed well in a rather lackluster week for the market.

    I recently created a list of companies with market capitalization in excess of $50mm at the beginning of May that derive a significant amount of their market value from cancer-related pursuits. ...

  • ADVENTRX Approved for New Cancer Drug Study

    (Wed, 27 Dec 2006 04:16:11 -0500)

    H.S. Ayoub submits: ADVENTRX Pharmaceuticals (ANX) announced early Tuesday that the FDA has accepted its Investigational New Drug [IND] application for a bioequivalence study of its cancer drug candidate ANX-530.

    The study will aim to compare ANX-530, a generic anti-cancer drug, to Navelbine, already approved for small cell cancers. The new study is to be initiated in 2007, and the company expects to file a New Drug Application [NDA] by the end of 2007.
    pills
    Preclinical studies of ANX-530 have shown the following conclusions:

    - Pharmacokinetics were unchanged between ANX-530 and...




Investor Clicks Financial Advertising
Investor Clicks Financial Advertising

News for ADVENTRX Pharmaceuticals, Inc. - Google Finance

News for ADVENTRX Pharmaceuticals, Inc. - Google Finance

News for ADVENTRX Pharmaceuticals, Inc. - Google Finance

MarketWatch.com - All MarketWatch News - ANX

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

MarketWatch.com - All MarketWatch News - ANX

Add as favourites (0) | Quote this article on your site

Be first to comment this article

Only registered users can write comments.
Please login or register.

ANX 



Reddit!Del.icio.us!Google!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Yahoo!Ma.gnolia!Free social bookmarking plugins and extensions for Joomla! websites!
 
[ Back ]

The Financial Ad Trader
The Financial Ad Trader - banner exchange
Member Of Candlestick Shop Banner Exchange

Stock Market Quotes
Starting...
Stock Market News
Popular Stocks
Random Stocks